Back
Eagle Pharmaceuticals 10K Form
Sell
14
EGRX
Eagle Pharmaceuticals
Last Price:
0.90
Seasonality Move:
-5.96%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-08-09 | 10Q | EGRX/Eagle Pharmaceuticals Quarterly |
2023-08-08 | 10Q | EGRX/Eagle Pharmaceuticals Quarterly |
2023-05-09 | 10Q | EGRX/Eagle Pharmaceuticals Quarterly |
2022-11-09 | 10Q | EGRX/Eagle Pharmaceuticals Quarterly |
2022-08-09 | 10Q | EGRX/Eagle Pharmaceuticals Quarterly |
2022-05-09 | 10Q | EGRX/Eagle Pharmaceuticals Quarterly |
Receive EGRX News And Ratings
See the #1 stock for the next 7 days that we like better than EGRX
EGRX Financial Statistics
Sales & Book Value
Annual Sales: | $316.61M |
---|---|
Cash Flow: | $0 |
Price / Cash Flow: | 0 |
Annual Sales: | $19.25 |
Price / Book: | 0 |
Profitability
EPS (TTM): | 0.91000 |
---|---|
Net Income (TTM): | $11.95M |
Gross Margin: | $221.67M |
Return on Equity: | 0% |
Return on Assets: | 0% |
Eagle Pharmaceuticals Earnings Forecast
Key Eagle Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 11 years for EGRX is 70.01%.
- The Selling, General & Administrative Expenses for EGRX have been equal to 33.68% of Gross Profit Margin.
- The Research & Development expenses have been 10.77% of Revenue.
- The Interest Expense is 11.35% of Operating Income.
- The Net Earning history of EGRX is 11.26% of Total Revenues.
- Per Share Earnings over the last 11 years have been positive in 4 years.
Eagle Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | OTCM |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | EGRX |
CUSIP: | 269796 |
Website: | eagleus.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
EGRX Technical Analysis vs Fundamental Analysis
Sell
14
Eagle Pharmaceuticals (EGRX)
is a Sell
Is Eagle Pharmaceuticals a Buy or a Sell?
-
Eagle Pharmaceuticals stock is rated a Sell
The current Eagle Pharmaceuticals [EGRX] share price is $0.65. The Score for EGRX is 14, which is 72% below its historic median score of 50, and infers higher risk than normal.